Spasticity

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia

Retrieved on: 
星期四, 五月 9, 2024
Biotechnology, General Health, Pharmaceutical, Health, Spasticity, Pain, FDA, Patient, CMS, Headache, Label, Death, Speech, ASPEN, Dysphagia, Therapy, Torticollis, Physician, Hubli railway division, Neurology, Medicare, Neurotoxin, MBA, Injection, Pharmaceutical industry

The launch marks Revance’s entry into the large and growing U.S. therapeutics neurotoxin market.

Key Points: 
  • The launch marks Revance’s entry into the large and growing U.S. therapeutics neurotoxin market.
  • “DAXXIFY provides a significant opportunity for Revance and marks the culmination of our decades-long mission to bring true innovation to the therapeutics market.
  • Following the FDA’s approval of DAXXIFY for cervical dystonia in August 2023, Revance launched the DAXXIFY cervical dystonia PrevU early experience program with the objective of optimizing treatment outcomes for patients and ensuring smooth practice integration.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

NIH Awards Hesperos Research Grant to Develop Animal-Free Botox Testing Platform

Retrieved on: 
星期二, 五月 7, 2024
Health, FDA, Stem Cells, Research, Science, Pharmaceutical, Biotechnology, NMJ, NIH, Safety, Food, Cell, Animal, Acetylcholine, Spasticity, Botulinum toxin, MLB, Santhanam, Neurotoxin, Brain cell, Strabismus, Biology, Paralysis, Drug development, NCATS, Migraine, Drug discovery, Neuromuscular junction, Pharmaceutical industry

The goal of the effort is to develop an advanced testing platform capable of assessing the potency of the Botulinum Toxin (BoT) without the need for animal testing.

Key Points: 
  • The goal of the effort is to develop an advanced testing platform capable of assessing the potency of the Botulinum Toxin (BoT) without the need for animal testing.
  • Despite its therapeutic benefits, BoT is one of the most potent neurotoxins known to man, necessitating stringent batch testing to ensure consistent potency.
  • By successfully developing a high-throughput, human-based platform, Hesperos endeavors to obviate the need for animal testing in this process while simultaneously enhancing the safety profile of BoT.
  • https://fda.gov
    The mission of National Center for Advancing Translational Sciences (NCATS) at NIH is to turn research observations into health solutions through translational science.

Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project

Retrieved on: 
星期五, 四月 26, 2024
Spasticity, Bacteriology, WARF, University, Dystonia, Publication, Partnership, Research, AB toxin, Hannover Medical School, Movement disorder, Professional, Acquisition, Jan Vansina, Hyperhidrosis, Migraine, Wisconsin Alumni Research Foundation, Canning

SEOUL, KOREA, April 26, 2024 (GLOBE NEWSWIRE) -- Dr. Eric A. Johnson and Professor Dirk Dressler, internationally renowned botulinum toxin experts, visited South Korea in March this year to join WizMedi Bio's new botulinum toxin development project.

Key Points: 
  • SEOUL, KOREA, April 26, 2024 (GLOBE NEWSWIRE) -- Dr. Eric A. Johnson and Professor Dirk Dressler, internationally renowned botulinum toxin experts, visited South Korea in March this year to join WizMedi Bio's new botulinum toxin development project.
  • The long-standing collaboration between Dr. Johnson and Professor Dressler has shaped the global botulinum toxin landscape over the past decades.
  • Dr. Johnson, a retired professor of bacteriology at the University of Wisconsin-Madison in the US, has dedicated over four decades to botulinum toxin research, authoring over 200 publications and founded 3 botulinum toxin companies.
  • Having introduced most of the major botulinum toxin drugs to the international markets, he is a highly sought-after consultant to the botulinum toxin industry.

Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy Annual Meeting

Retrieved on: 
星期二, 四月 23, 2024
Spasticity, Systemic disease, Date, Safety, Abstract (summary), Tropism, Abstract, Microfluidics, Outline, Cell, AAV, Oral medicine, Gene, Society, IPSC, DSM-IV codes, Brain cell, Neuron, Annual general meeting, Therapy, Vaccine

Andy Murray, Ph.D, CEO & Co-Founder of Sania Therapeutics, said: “Since our official launch last May, we have been pressing ahead with developing truly differentiated AAV gene therapies.

Key Points: 
  • Andy Murray, Ph.D, CEO & Co-Founder of Sania Therapeutics, said: “Since our official launch last May, we have been pressing ahead with developing truly differentiated AAV gene therapies.
  • Sania’s approach, using its R-Scan platform, is focused on generating novel, targeted vectors that can be successfully and rapidly translated into the clinic.
  • It combines human induced pluripotent stem cell derived cell types and microfluidics to perform directed AAV capsid evolution in an in vitro human system.
  • It combines an intramuscular injection of AAV gene therapy with oral medicine to selectively reduce excitability in targeted motor neurons.

Texas Original Announces Opening of Sugar Land Location, Launches New RSO Gummies

Retrieved on: 
星期三, 三月 27, 2024
Vitamins, Supplements, Tobacco, Cannabis, Alternative Medicine, General Health, Pharmaceutical, Health, Retail, Natural Resources, Oncology, Dark, Epilepsy, Spasticity, Cannabinoid, RSO, Patient, Flavonoid, Cancer, Terpene, Protein, Originality, THC, Physician, PTSD, Diabetic neuropathy, Medicinal plants

Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest prescription pickup location in Sugar Land, Texas.

Key Points: 
  • Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest prescription pickup location in Sugar Land, Texas.
  • Texas Original also announced the launch of its new Pineapple Gummies, a 20 mg THC-only product made with Rick Simpson Oil (RSO).
  • Alongside the company’s recently launched Dark Chocolate Bites and RSO Tincture, Texas Original’s Pineapple Gummies are among the first medical cannabis products in the state—and the first gummy product—to incorporate RSO.
  • Texans can obtain medical cannabis prescriptions through online clinics or local physicians registered with the Compassionate Use Registry of Texas.

LuskinOIC Partners with the Center for Cerebral Palsy at UCLA to Host Annual Cerebral Palsy Professional Conference and Family Forum on March 23

Retrieved on: 
星期二, 三月 19, 2024
Family, Health, Consumer, Neurology, Other Health, Children, General Health, Community, Knee, Spasticity, DPT, Cerebral palsy, Conference, Neurotoxin, PCS, Doctor of Philosophy, MD, Functional, Physical disability, CP, Bangladesh Technical Education Board, Active Life: Outdoor Challenge, UCLA, Social

On Saturday, March 23, 2024, LuskinOIC and the Center for Cerebral Palsy at UCLA will offer education for professionals, people with cerebral palsy and family members affected by cerebral palsy.

Key Points: 
  • On Saturday, March 23, 2024, LuskinOIC and the Center for Cerebral Palsy at UCLA will offer education for professionals, people with cerebral palsy and family members affected by cerebral palsy.
  • The conference takes place during National Cerebral Palsy Awareness month.
  • Registration is required for both the Professional Conference Agenda & Registration and Family Forum Agenda & Registration .
  • Symposium sponsors include the Cerebral Palsy Foundation, the Shapiro Family Foundation, and the Tarjan Center.

Texas Original Opens New San Antonio Location, Launches Dark Chocolate Bites

Retrieved on: 
星期三, 二月 14, 2024
Alternative Medicine, Retail, Health, Cannabis, Vitamins, Supplements, Online Retail, Pharmaceutical, Oncology, Mental Health, Other Retail, Physical Therapy, General Health, Natural Resources, Food, Beverage, Dark, Originality, Physician, Flavonoid, Diabetic neuropathy, Cannabinoid, Spasticity, Terpene, Chronic pain, Blue Dream, Patient, THC, Protein, Epilepsy, PTSD, RSO, Cancer, Drug

Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest permanent prescription pickup location in San Antonio.

Key Points: 
  • Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest permanent prescription pickup location in San Antonio.
  • Texas Original also announced the launch of its new Dark Chocolate Bites, the company’s first chocolate product and the state’s first medical cannabis chocolate product made with Rick Simpson Oil (RSO).
  • Like all Texas Original products, Dark Chocolate Bites are regulated and rigorously tested to ensure quality, consistency and purity.
  • The northeast San Antonio location is Texas Original’s third medical cannabis pickup location in the San Antonio area, joining the company’s existing locations in west San Antonio and Universal City.

Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®

Retrieved on: 
星期五, 二月 2, 2024
Neurology, FDA, Public Relations, Investor Relations, Clinical Trials, Communications, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Injection, Spasticity, Government, Therapy, Patient, Safety, Incidence, Torticollis, American Academy, Neurotoxin, Speech, ASPEN, Food, Physician, Total, Muscle weakness, CMS, Death, MHSA, Food and Drug Administration, Hubli railway division, Dysphagia, Pharmaceutical industry

The company also announced today the publication of results from the ASPEN-1 Pivotal Phase 3 study in Neurology®, the medical journal of the American Academy of Neurology.

Key Points: 
  • The company also announced today the publication of results from the ASPEN-1 Pivotal Phase 3 study in Neurology®, the medical journal of the American Academy of Neurology.
  • “Importantly, the real-world clinical results of DAXXIFY from the patients I have injected so far in PrevU, including safety, efficacy and duration, are in-line with those seen in the ASPEN-1 study.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.
  • To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669.

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

Retrieved on: 
星期一, 一月 8, 2024
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Patient, Fosun International, RHA, Collection, Dysphagia, Neurotoxin, FDA, Hubli railway division, Ageing, Torticollis, Therapy, Education, Death, Speech, COVID-19, Adjustment, Spasticity, Growth, Investment, Lip, Finance, PMA, GAAP, Hyaluronic acid

Revance Therapeutics , Inc. (NASDAQ:RVNC) today provided a corporate update as well as preliminary unaudited fourth quarter and full year 2023 financial results, 2024 guidance and financial outlook.

Key Points: 
  • Revance Therapeutics , Inc. (NASDAQ:RVNC) today provided a corporate update as well as preliminary unaudited fourth quarter and full year 2023 financial results, 2024 guidance and financial outlook.
  • We wish Dustin the best in his new endeavors.”
    Corporate Updates and Preliminary Q4 and FY 2023 Financial Results:
    Revance expects Q4 2023 preliminary unaudited DAXXIFY revenue to be between $23.5 million and $24.5 million.
  • Full year 2023 preliminary unaudited DAXXIFY revenue is expected to be between $83.5 million and $84.5 million.
  • Revance expects preliminary unaudited fourth quarter 2023 RHA Collection revenue to be between $34 million and $35 million, and full year preliminary unaudited 2023 RHA Collection revenue to be between $128 million and $129 million.

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases

Retrieved on: 
星期四, 一月 4, 2024
FDA, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Alcoholism, Atopic dermatitis, Cholesterol, Metabolism, Multimedia, IND, Alcoholic hepatitis, Disease, Mortality, AMD, Body surface area, Therapy, MELD, Clinical trial, Hospital, Telecanthus, DSM-IV codes, Spasticity, Protocol, Cirrhosis, Biomarker, Triglyceride, Syndrome, Ethanol, Patient, Safety, RASP, Retina, Pharmaceutical industry

ADX-629, administered twice daily over 90 days, has completed initial clinical testing in three adult patients in an investigator-sponsored clinical trial.

Key Points: 
  • ADX-629, administered twice daily over 90 days, has completed initial clinical testing in three adult patients in an investigator-sponsored clinical trial.
  • Highlighting the advancement of the RASP platform and the selection of key clinical indications for future development, Aldeyra released a focused pipeline.
  • “With the success achieved in our ADX-629 program, which includes a number of positive, signal-finding clinical results, we are excited to advance our RASP modulator pipeline to systemic and retinal immune-mediated diseases, as well as metabolic diseases, exacerbated by RASP,” stated Dr. Brady.
  • “We anticipate 2024 to provide a variety of clinical-stage catalysts, as Aldeyra continues to progress its novel RASP platform.”